Username

Password

Forgot Password?

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Keld Danø

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Chemicals & Drugs

Living Beings

Mice

Anatomy

Genes & Molecular Sequences

Amino Acid Sequence

Concepts & Ideas

Procedures

Disorders

Breast Neoplasms

Sign-in to see full Profile

Network (preview)

Co-Publications
Name
42
Lund, Leif
38
Behrendt, Niels
29
Høyer-Hansen, Gunilla
29
Ploug, Michael
26
Rønne, E
22
Rømer, John
22
Nielsen, Boye
21
Pyke, C
21
Grøndahl-Hansen, J
18
Brünner, Nils
12
Gårdsvoll, Henrik
10
Bugge, Thomas
10
Stephens, Ross
9
Ralfkiaer, Elisabeth
9
Christensen, Ib Jarle

Sign-in to see all Coauthors

Publications

TOP 3
Illemann Martin; Bird Nigel; Majeed Ali; Laerum Ole D; Lund Leif R; Danø Keld; Nielsen Boye Schnack
Two distinct expression patterns of urokinase, urokinase receptor and plasminogen activator inhibitor-1 in colon cancer liver metastases.
Laerum Ole D; Illemann Martin; Skarstein Arne; Helgeland Lars; Ovrebø Kjell; Danø Keld; Nielsen Boye S
Crohn's disease but not chronic ulcerative colitis induces the expression of PAI-1 in enteric neurons.
Almholt Kasper; Juncker-Jensen Anna; Laerum Ole Didrik; Danø Keld; Johnsen Morten; Lund Leif Røge; Rømer John
Metastasis is strongly reduced by the matrix metalloproteinase inhibitor Galardin in the MMTV-PymT transgenic breast cancer model.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Keld Danø (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Illemann Martin; Bird Nigel; Majeed Ali; Laerum Ole D; Lund Leif R; Danø Keld; Nielsen Boye Schnack
Two distinct expression patterns of urokinase, urokinase receptor and plasminogen activator inhibitor-1 in colon cancer liver metastases.
International journal of cancer. Journal international du cancer 2009;124(8):1860-70.
2008: Laerum Ole D; Illemann Martin; Skarstein Arne; Helgeland Lars; Ovrebø Kjell; Danø Keld; Nielsen Boye S
Crohn's disease but not chronic ulcerative colitis induces the expression of PAI-1 in enteric neurons.
The American journal of gastroenterology 2008;103(9):2350-8.
2008: Almholt Kasper; Juncker-Jensen Anna; Laerum Ole Didrik; Danø Keld; Johnsen Morten; Lund Leif Røge; Rømer John
Metastasis is strongly reduced by the matrix metalloproteinase inhibitor Galardin in the MMTV-PymT transgenic breast cancer model.
Molecular cancer therapeutics 2008;7(9):2758-67.
2008: Hillig Thore; Engelholm Lars H; Ingvarsen Signe; Madsen Daniel H; Gårdsvoll Henrik; Larsen Jørgen K; Ploug Michael; Danø Keld; Kjøller Lars; Behrendt Niels
A composite role of vitronectin and urokinase in the modulation of cell morphology upon expression of the urokinase receptor.
The Journal of biological chemistry 2008;283(22):15217-23.
2007: Heissig Beate; Lund Leif R; Akiyama Haruyo; Ohki Makiko; Morita Yohei; Rømer John; Nakauchi Hiromitsu; Okumura Ko; Ogawa Hideoki; Werb Zena; Danø Keld; Hattori Koichi
The plasminogen fibrinolytic pathway is required for hematopoietic regeneration.
Cell stem cell 2007;1(6):658-70.
2007: Jögi A; Pass J; Høyer-Hansen G; Lund L R; Nielsen B S; Danø K; Rømer J
Systemic administration of anti-urokinase plasminogen activator receptor monoclonal antibodies induces hepatic fibrin deposition in tissue-type plasminogen activator deficient mice.
Journal of thrombosis and haemostasis : JTH 2007;5(9):1936-44.
2007: Pass Jesper; Jögi Annika; Lund Ida K; Rønø Birgitte; Rasch Morten G; Gårdsvoll Henrik; Lund Leif R; Ploug Michael; Rømer John; Danø Keld; Høyer-Hansen Gunilla
Murine monoclonal antibodies against murine uPA receptor produced in gene-deficient mice: inhibitory effects on receptor-mediated uPA activity in vitro and in vivo.
Thrombosis and haemostasis 2007;97(6):1013-22.
2007: Nielsen Boye S; Rank Fritz; Illemann Martin; Lund Leif R; Danø Keld
Stromal cells associated with early invasive foci in human mammary ductal carcinoma in situ coexpress urokinase and urokinase receptor.
International journal of cancer. Journal international du cancer 2007;120(10):2086-95.
2006: Lund Leif R; Green Kirsty A; Stoop Allart A; Ploug Michael; Almholt Kasper; Lilla Jennifer; Nielsen Boye S; Christensen Ib J; Craik Charles S; Werb Zena; Danø Keld; Rømer John
Plasminogen activation independent of uPA and tPA maintains wound healing in gene-deficient mice.
The EMBO journal 2006;25(12):2686-97.
2006: Illemann Martin; Bird Nigel; Majeed Ali; Sehested Maxwell; Laerum Ole D; Lund Leif R; Danø Keld; Nielsen Boye Schnack
MMP-9 is differentially expressed in primary human colorectal adenocarcinomas and their metastases.
Molecular cancer research : MCR 2006;4(5):293-302.
2006: Piironen Timo; Haese Alexander; Huland Hartwig; Steuber Thomas; Christensen Ib Jarle; Brünner Nils; Danø Keld; Høyer-Hansen Gunilla; Lilja Hans
Enhanced discrimination of benign from malignant prostatic disease by selective measurements of cleaved forms of urokinase receptor in serum.
Clinical chemistry 2006;52(5):838-44.
2005: Pedersen Tanja Xenia; Pennington Caroline J; Almholt Kasper; Christensen Ib Jarle; Nielsen Boye Schnack; Edwards Dylan R; Rømer John; Danø Keld; Johnsen Morten
Extracellular protease mRNAs are predominantly expressed in the stromal areas of microdissected mouse breast carcinomas.
Carcinogenesis 2005;26(7):1233-40.
2005: Almasi Charlotte Elberling; Høyer-Hansen Gunilla; Christensen Ib Jarle; Danø Keld; Pappot Helle
Prognostic impact of liberated domain I of the urokinase plasminogen activator receptor in squamous cell lung cancer tissue.
Lung cancer (Amsterdam, Netherlands) 2005;48(3):349-55.
2005: Llinas Paola; Le Du Marie Hélène; Gårdsvoll Henrik; Danø Keld; Ploug Michael; Gilquin Bernard; Stura Enrico A; Ménez André
Crystal structure of the human urokinase plasminogen activator receptor bound to an antagonist peptide.
The EMBO journal 2005;24(9):1655-63.
2005: Danø Keld; Behrendt Niels; Høyer-Hansen Gunilla; Johnsen Morten; Lund Leif R; Ploug Michael; Rømer John
Plasminogen activation and cancer.
Thrombosis and haemostasis 2005;93(4):676-81.
2005: Usher Pernille Autzen; Thomsen Ole Frøkjaer; Iversen Peter; Johnsen Morten; Brünner Nils; Høyer-Hansen Gunilla; Andreasen Peter; Danø Keld; Nielsen Boye Schnack
Expression of urokinase plasminogen activator, its receptor and type-1 inhibitor in malignant and benign prostate tissue.
International journal of cancer. Journal international du cancer 2005;113(6):870-80.
2005: Almholt Kasper; Lund Leif R; Rygaard Jørgen; Nielsen Boye S; Danø Keld; Rømer John; Johnsen Morten
Reduced metastasis of transgenic mammary cancer in urokinase-deficient mice.
International journal of cancer. Journal international du cancer 2005;113(4):525-32.
2004: Jørgensen Thomas J D; Gårdsvoll Henrik; Danø Keld; Roepstorff Peter; Ploug Michael
Dynamics of urokinase receptor interaction with Peptide antagonists studied by amide hydrogen exchange and mass spectrometry.
Biochemistry 2004;43(47):15044-57.
2004: Piironen Timo; Laursen Birgitte; Pass Jesper; List Karin; Gårdsvoll Henrik; Ploug Michael; Danø Keld; Høyer-Hansen Gunilla
Specific immunoassays for detection of intact and cleaved forms of the urokinase receptor.
Clinical chemistry 2004;50(11):2059-68.
2004: Illemann Martin; Hansen Ulla; Nielsen Hans Jørgen; Andreasen Peter A; Høyer-Hansen Gunilla; Lund Leif R; Danø Keld; Nielsen Boye Schnack
Leading-edge myofibroblasts in human colon cancer express plasminogen activator inhibitor-1.
American journal of clinical pathology 2004;122(2):256-65.
2004: Hansen Line V; Gårdsvoll Henrik; Nielsen Boye S; Lund Leif R; Danø Keld; Jensen Ole N; Ploug Michael
Structural analysis and tissue localization of human C4.4A: a protein homologue of the urokinase receptor.
The Biochemical journal 2004;380(Pt 3):845-57.
2004: Gårdsvoll Henrik; Werner Finn; Søndergaard Leif; Danø Keld; Ploug Michael
Characterization of low-glycosylated forms of soluble human urokinase receptor expressed in Drosophila Schneider 2 cells after deletion of glycosylation-sites.
Protein expression and purification 2004;34(2):284-95.
2004: Kjøller Lars; Engelholm Lars H; Høyer-Hansen Maria; Danø Keld; Bugge Thomas H; Behrendt Niels
uPARAP/endo180 directs lysosomal delivery and degradation of collagen IV.
Experimental cell research 2004;293(1):106-16.
2003: Pass J; Gårdsvoll H; Lund L R; Danø K; Høyer-Hansen G
Generation of antibodies to the urokinase receptor (uPAR) by DNA immunization of uPAR knockout mice: membrane-bound uPAR is not required for an antibody response.
Scandinavian journal of immunology 2003;58(3):298-305.
2003: Solberg Helene; Rinkenberger Julie; Danø Keld; Werb Zena; Lund Leif R
A functional overlap of plasminogen and MMPs regulates vascularization during placental development.
Development (Cambridge, England) 2003;130(18):4439-50.
2003: Almholt Kasper; Nielsen Boye S; Frandsen Thomas L; Brünner Nils; Danø Keld; Johnsen Morten
Metastasis of transgenic breast cancer in plasminogen activator inhibitor-1 gene-deficient mice.
Oncogene 2003;22(28):4389-97.
2003: Pedersen Tanja Xenia; Leethanakul Chidchanop; Patel Vyomesh; Mitola David; Lund Leif Røge; Danø Keld; Johnsen Morten; Gutkind J Silvio; Bugge Thomas Henrik
Laser capture microdissection-based in vivo genomic profiling of wound keratinocytes identifies similarities and differences to squamous cell carcinoma.
Oncogene 2003;22(25):3964-76.
2003: Behrendt Niels; List Karin; Andreasen Peter A; Danø Keld
The pro-urokinase plasminogen-activation system in the presence of serpin-type inhibitors and the urokinase receptor: rescue of activity through reciprocal pro-enzyme activation.
The Biochemical journal 2003;371(Pt 2):277-87.
2003: Engelholm Lars H; List Karin; Netzel-Arnett Sarah; Cukierman Edna; Mitola David J; Aaronson Hannah; Kjøller Lars; Larsen Jørgen K; Yamada Kenneth M; Strickland Dudley K; Holmbeck Kenn; Danø Keld; Birkedal-Hansen Henning; Behrendt Niels; Bugge Thomas H
uPARAP/Endo180 is essential for cellular uptake of collagen and promotes fibroblast collagen adhesion.
The Journal of cell biology 2003;160(7):1009-15.
2002: Ploug M; Gårdsvoll H; Jørgensen T J D; Lønborg Hansen L; Danø K
Structural analysis of the interaction between urokinase-type plasminogen activator and its receptor: a potential target for anti-invasive cancer therapy.
Biochemical Society transactions 2002;30(2):177-83.
2002: Schnack Nielsen Boye; Rank Fritz; Engelholm Lars H; Holm Arne; Danø Keld; Behrendt Niels
Urokinase receptor-associated protein (uPARAP) is expressed in connection with malignant as well as benign lesions of the human breast and occurs in specific populations of stromal cells.
International journal of cancer. Journal international du cancer 2002;98(5):656-64.
2001: Nielsen B S; Sehested M; Duun S; Rank F; Timshel S; Rygaard J; Johnsen M; Danø K
Urokinase plasminogen activator is localized in stromal cells in ductal breast cancer.
Laboratory investigation; a journal of technical methods and pathology 2001;81(11):1485-501.
2001: Engelholm L H; Nielsen B S; Netzel-Arnett S; Solberg H; Chen X D; Lopez Garcia J M; Lopez-Otin C; Young M F; Birkedal-Hansen H; Danø K; Lund L R; Behrendt N; Bugge T H
The urokinase plasminogen activator receptor-associated protein/endo180 is coexpressed with its interaction partners urokinase plasminogen activator receptor and matrix metalloprotease-13 during osteogenesis.
Laboratory investigation; a journal of technical methods and pathology 2001;81(10):1403-14.
2001: Nielsen B S; Rank F; López J M; Balbin M; Vizoso F; Lund L R; Danø K; López-Otín C
Collagenase-3 expression in breast myofibroblasts as a molecular marker of transition of ductal carcinoma in situ lesions to invasive ductal carcinomas.
Cancer research 2001;61(19):7091-100.
2001: Ploug M; Østergaard S; Gårdsvoll H; Kovalski K; Holst-Hansen C; Holm A; Ossowski L; Danø K
Peptide-derived antagonists of the urokinase receptor. affinity maturation by combinatorial chemistry, identification of functional epitopes, and inhibitory effect on cancer cell intravasation.
Biochemistry 2001;40(40):12157-68.
2001: Høyer-Hansen G; Pessara U; Holm A; Pass J; Weidle U; Danø K; Behrendt N
Urokinase-catalysed cleavage of the urokinase receptor requires an intact glycolipid anchor.
The Biochemical journal 2001;358(Pt 3):673-9.
2001: Rømer J; Pyke C; Lund L R; Ralfkiaer E; Danø K
Cancer cell expression of urokinase-type plasminogen activator receptor mRNA in squamous cell carcinomas of the skin.
The Journal of investigative dermatology 2001;116(3):353-8.
2001: Engelholm L H; Nielsen B S; Danø K; Behrendt N
The urokinase receptor associated protein (uPARAP/endo180): a novel internalization receptor connected to the plasminogen activation system.
Trends in cardiovascular medicine 2001;11(1):7-13.
2000: Pedersen A N; Christensen I J; Stephens R W; Briand P; Mouridsen H T; Danø K; Brünner N
The complex between urokinase and its type-1 inhibitor in primary breast cancer: relation to survival.
Cancer research 2000;60(24):6927-34.
2000: Lund L R; Bjørn S F; Sternlicht M D; Nielsen B S; Solberg H; Usher P A; Osterby R; Christensen I J; Stephens R W; Bugge T H; Danø K; Werb Z
Lactational competence and involution of the mouse mammary gland require plasminogen.
Development (Cambridge, England) 2000;127(20):4481-92.
2000: Høyer-Hansen G; Hamers M J; Pedersen A N; Nielsen H J; Brünner N; Danø K; Stephens R W
Loss of ELISA specificity due to biotinylation of monoclonal antibodies.
Journal of immunological methods 2000;235(1-2):91-9.
2000: List K; Jensen O N; Bugge T H; Lund L R; Ploug M; Danø K; Behrendt N
Plasminogen-independent initiation of the pro-urokinase activation cascade in vivo. Activation of pro-urokinase by glandular kallikrein (mGK-6) in plasminogen-deficient mice.
Biochemistry 2000;39(3):508-15.
2000: Behrendt N; Jensen O N; Engelholm L H; Mørtz E; Mann M; Danø K
A urokinase receptor-associated protein with specific collagen binding properties.
The Journal of biological chemistry 2000;275(3):1993-2002.
1999: Gårdsvoll H; Danø K; Ploug M
Mapping part of the functional epitope for ligand binding on the receptor for urokinase-type plasminogen activator by site-directed mutagenesis.
The Journal of biological chemistry 1999;274(53):37995-8003.
1999: Lund L R; Romer J; Bugge T H; Nielsen B S; Frandsen T L; Degen J L; Stephens R W; Danø K
Functional overlap between two classes of matrix-degrading proteases in wound healing.
The EMBO journal 1999;18(17):4645-56.
1999: Stephens R W; Nielsen H J; Christensen I J; Thorlacius-Ussing O; Sørensen S; Danø K; Brünner N
Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis.
Journal of the National Cancer Institute 1999;91(10):869-74.
1999: Danø K; Rømer J; Nielsen B S; Bjørn S; Pyke C; Rygaard J; Lund L R
Cancer invasion and tissue remodeling--cooperation of protease systems and cell types.
APMIS : acta pathologica, microbiologica, et immunologica Scandinavica 1999;107(1):120-7.
1999: List K; Høyer-Hansen G; Rønne E; Danø K; Behrendt N
Different mechanisms are involved in the antibody mediated inhibition of ligand binding to the urokinase receptor: a study based on biosensor technology.
Journal of immunological methods 1999;222(1-2):125-33.
1998: Johnsen M; Lund L R; Rømer J; Almholt K; Danø K
Cancer invasion and tissue remodeling: common themes in proteolytic matrix degradation.
Current opinion in cell biology 1998;10(5):667-71.
1998: Gårdsvoll H; van Zonneveld A J; Holm A; Eldering E; van Meijer M; Danø K; Pannekoek H
Selection of peptides that bind to plasminogen activator inhibitor 1 (PAI-1) using random peptide phage-display libraries.
FEBS letters 1998;431(2):170-4.
1998: Bugge T H; Lund L R; Kombrinck K K; Nielsen B S; Holmbäck K; Drew A F; Flick M J; Witte D P; Danø K; Degen J L
Reduced metastasis of Polyoma virus middle T antigen-induced mammary cancer in plasminogen-deficient mice.
Oncogene 1998;16(24):3097-104.
1998: Ploug M; Ostergaard S; Hansen L B; Holm A; Danø K
Photoaffinity labeling of the human receptor for urokinase-type plasminogen activator using a decapeptide antagonist. Evidence for a composite ligand-binding site and a short interdomain separation.
Biochemistry 1998;37(11):3612-22.
1997: Høyer-Hansen G; Behrendt N; Ploug M; Danø K; Preissner K T
The intact urokinase receptor is required for efficient vitronectin binding: receptor cleavage prevents ligand interaction.
FEBS letters 1997;420(1):79-85.
1997: Nielsen B S; Sehested M; Kjeldsen L; Borregaard N; Rygaard J; Danø K
Expression of matrix metalloprotease-9 in vascular pericytes in human breast cancer.
Laboratory investigation; a journal of technical methods and pathology 1997;77(4):345-55.
1997: Stephens R W; Pedersen A N; Nielsen H J; Hamers M J; Høyer-Hansen G; Rønne E; Dybkjaer E; Danø K; Brünner N
ELISA determination of soluble urokinase receptor in blood from healthy donors and cancer patients.
Clinical chemistry 1997;43(10):1868-76.
1997: Bjørn S F; Hastrup N; Lund L R; Danø K; Larsen J F; Pyke C
Co-ordinated expression of MMP-2 and its putative activator, MT1-MMP, in human placentation.
Molecular human reproduction 1997;3(8):713-23.
1997: de Witte H; Pappot H; Brünner N; Grøndahl-Hansen J; Hoyer-Hansen G; Behrendt N; Guldhammer-Skov B; Sweep F; Benraad T; Danø K
ELISA for complexes between urokinase-type plasminogen activator and its receptor in lung cancer tissue extracts.
International journal of cancer. Journal international du cancer 1997;72(3):416-23.
1997: Pappot H; Høyer-Hansen G; Rønne E; Hansen H H; Brünner N; Danø K; Grøndahl-Hansen J
Elevated plasma levels of urokinase plasminogen activator receptor in non-small cell lung cancer patients.
European journal of cancer (Oxford, England : 1990) 1997;33(6):867-72.
1997: Pedersen A N; Høyer-Hansen G; Brünner N; Clark G M; Larsen B; Poulsen H S; Danø K; Stephens R W
The complex between urokinase plasminogen activator and its type-1 inhibitor in breast cancer extracts quantitated by ELISA.
Journal of immunological methods 1997;203(1):55-65.
1997: Grøndahl-Hansen J; Christensen I J; Briand P; Pappot H; Mouridsen H T; Blichert-Toft M; Danø K; Brünner N
Plasminogen activator inhibitor type 1 in cytosolic tumor extracts predicts prognosis in low-risk breast cancer patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(2):233-9.
1997: Behrendt N; Danø K
Reply to comment on 'Effect of purified, soluble urokinase receptor on the plasminogen-prourokinase activation system' (A. A-R. Higazi)
FEBS letters 1997;402(2-3):293-4.
1997: Høyer-Hansen G; Ploug M; Behrendt N; Rønne E; Danø K
Cell-surface acceleration of urokinase-catalyzed receptor cleavage.
European journal of biochemistry / FEBS 1997;243(1-2):21-6.
1996: Behrendt N; Danø K
Effect of purified, soluble urokinase receptor on the plasminogen-prourokinase activation system.
FEBS letters 1996;393(1):31-6.
1996: Rømer J; Bugge T H; Pyke C; Lund L R; Flick M J; Degen J L; Danø K
Plasminogen and wound healing.
Nature medicine 1996;2(7):725.
1996: Nielsen B S; Sehested M; Timshel S; Pyke C; Danø K
Messenger RNA for urokinase plasminogen activator is expressed in myofibroblasts adjacent to cancer cells in human breast cancer.
Laboratory investigation; a journal of technical methods and pathology 1996;74(1):168-77.
1996: Nielsen B S; Timshel S; Kjeldsen L; Sehested M; Pyke C; Borregaard N; Danø K
92 kDa type IV collagenase (MMP-9) is expressed in neutrophils and macrophages but not in malignant epithelial cells in human colon cancer.
International journal of cancer. Journal international du cancer 1996;65(1):57-62.
1995: Ploug M; Rahbek-Nielsen H; Ellis V; Roepstorff P; Danø K
Chemical modification of the urokinase-type plasminogen activator and its receptor using tetranitromethane. Evidence for the involvement of specific tyrosine residues in both molecules during receptor-ligand interaction.
Biochemistry 1995;34(39):12524-34.
1995: Pyke C; Salo S; Ralfkiaer E; Rømer J; Danø K; Tryggvason K
Laminin-5 is a marker of invading cancer cells in some human carcinomas and is coexpressed with the receptor for urokinase plasminogen activator in budding cancer cells in colon adenocarcinomas.
Cancer research 1995;55(18):4132-9.
1995: Lund L R; Ellis V; Rønne E; Pyke C; Danø K
Transcriptional and post-transcriptional regulation of the receptor for urokinase-type plasminogen activator by cytokines and tumour promoters in the human lung carcinoma cell line A549.
The Biochemical journal 1995;310 ( Pt 1)():345-52.
1995: Bugge T H; Suh T T; Flick M J; Daugherty C C; Rømer J; Solberg H; Ellis V; Danø K; Degen J L
The receptor for urokinase-type plasminogen activator is not essential for mouse development or fertility.
The Journal of biological chemistry 1995;270(28):16886-94.
1995: Behrendt N; Rønne E; Danø K
The structure and function of the urokinase receptor, a membrane protein governing plasminogen activation on the cell surface.
Biological chemistry Hoppe-Seyler 1995;376(5):269-79.
1995: Rønne E; Pappot H; Grøndahl-Hansen J; Høyer-Hansen G; Plesner T; Hansen N E; Danø K
The receptor for urokinase plasminogen activator is present in plasma from healthy donors and elevated in patients with paroxysmal nocturnal haemoglobinuria.
British journal of haematology 1995;89(3):576-81.
1994: Pyke C; Rømer J; Kallunki P; Lund L R; Ralfkiaer E; Danø K; Tryggvason K
The gamma 2 chain of kalinin/laminin 5 is preferentially expressed in invading malignant cells in human cancers.
The American journal of pathology 1994;145(4):782-91.
1994: Suh T T; Nerlov C; Danø K; Degen J L
The murine urokinase-type plasminogen activator receptor gene.
The Journal of biological chemistry 1994;269(42):25992-8.
1994: Pedersen H; Brünner N; Francis D; Osterlind K; Rønne E; Hansen H H; Danø K; Grøndahl-Hansen J
Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue.
Cancer research 1994;54(17):4671-5.
1994: Solberg H; Rømer J; Brünner N; Holm A; Sidenius N; Danø K; Høyer-Hansen G
A cleaved form of the receptor for urokinase-type plasminogen activator in invasive transplanted human and murine tumors.
International journal of cancer. Journal international du cancer 1994;58(6):877-81.
1994: Ploug M; Ellis V; Danø K
Ligand interaction between urokinase-type plasminogen activator and its receptor probed with 8-anilino-1-naphthalenesulfonate. Evidence for a hydrophobic binding site exposed only on the intact receptor.
Biochemistry 1994;33(30):8991-7.
1994: Rømer J; Pyke C; Lund L R; Eriksen J; Kristensen P; Rønne E; Høyer-Hansen G; Danø K; Brünner N
Expression of uPA and its receptor by both neoplastic and stromal cells during xenograft invasion.
International journal of cancer. Journal international du cancer 1994;57(4):553-60.
1994: Rømer J; Lund L R; Eriksen J; Pyke C; Kristensen P; Danø K
The receptor for urokinase-type plasminogen activator is expressed by keratinocytes at the leading edge during re-epithelialization of mouse skin wounds.
The Journal of investigative dermatology 1994;102(4):519-22.
1994: Rønne E; Behrendt N; Ploug M; Nielsen H J; Wöllisch E; Weidle U; Danø K; Høyer-Hansen G
Quantitation of the receptor for urokinase plasminogen activator by enzyme-linked immunosorbent assay.
Journal of immunological methods 1994;167(1-2):91-101.
1994: Pedersen H; Grøndahl-Hansen J; Francis D; Osterlind K; Hansen H H; Danø K; Brünner N
Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma.
Cancer research 1994;54(1):120-3.
1994: Brünner N; Pyke C; Hansen C H; Rømer J; Grøndahl-Hansen J; Danø K
Urokinase plasminogen activator (uPA) and its type 1 inhibitor (PAI-1): regulators of proteolysis during cancer invasion and prognostic parameters in breast cancer.
Cancer treatment and research 1994;71():299-309.
1993: Ellis V; Danø K
Specific inhibition of the activity of the urokinase receptor-mediated cell-surface plasminogen activation system by suramin.
The Biochemical journal 1993;296 ( Pt 2)():505-10.
1993: Behrendt N; Rønne E; Danø K
A novel, specific pro-urokinase complex on monocyte-like cells, detected by transglutaminase-catalyzed cross-linking.
FEBS letters 1993;336(3):394-6.
1993: Myöhänen H T; Stephens R W; Hedman K; Tapiovaara H; Rønne E; Høyer-Hansen G; Danø K; Vaheri A
Distribution and lateral mobility of the urokinase-receptor complex at the cell surface.
The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 1993;41(9):1291-301.
1993: Ploug M; Kjalke M; Rønne E; Weidle U; Høyer-Hansen G; Danø K
Localization of the disulfide bonds in the NH2-terminal domain of the cellular receptor for human urokinase-type plasminogen activator. A domain structure belonging to a novel superfamily of glycolipid-anchored membrane proteins.
The Journal of biological chemistry 1993;268(23):17539-46.
1993: Pyke C; Eriksen J; Solberg H; Nielsen B S; Kristensen P; Lund L R; Danø K
An alternatively spliced variant of mRNA for the human receptor for urokinase plasminogen activator.
FEBS letters 1993;326(1-3):69-74.
1993: Grøndahl-Hansen J; Christensen I J; Rosenquist C; Brünner N; Mouridsen H T; Danø K; Blichert-Toft M
High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis.
Cancer research 1993;53(11):2513-21.
1993: Pyke C; Graem N; Ralfkiaer E; Rønne E; Høyer-Hansen G; Brünner N; Danø K
Receptor for urokinase is present in tumor-associated macrophages in ductal breast carcinoma.
Cancer research 1993;53(8):1911-5.
1993: Ellis V; Danø K
Potentiation of plasminogen activation by an anti-urokinase monoclonal antibody due to ternary complex formation. A mechanistic model for receptor-mediated plasminogen activation.
The Journal of biological chemistry 1993;268(7):4806-13.
1993: Behrendt N; Rønne E; Danø K
Binding of the urokinase-type plasminogen activator to its cell surface receptor is inhibited by low doses of suramin.
The Journal of biological chemistry 1993;268(8):5985-9.
1993: Pyke C; Ralfkiaer E; Tryggvason K; Danø K
Messenger RNA for two type IV collagenases is located in stromal cells in human colon cancer.
The American journal of pathology 1993;142(2):359-65.
1993: Ellis V; Behrendt N; Danø K
Cellular receptor for urokinase-type plasminogen activator: function in cell-surface proteolysis.
Methods in enzymology 1993;223():223-33.
1993: Behrendt N; Ploug M; Rønne E; Høyer-Hansen G; Danø K
Cellular receptor for urokinase-type plasminogen activator: protein structure.
Methods in enzymology 1993;223():207-22.
1992: Ellis V; Pyke C; Eriksen J; Solberg H; Danø K
The urokinase receptor: involvement in cell surface proteolysis and cancer invasion.
Annals of the New York Academy of Sciences 1992;667():13-31.
1992: Høyer-Hansen G; Rønne E; Solberg H; Behrendt N; Ploug M; Lund L R; Ellis V; Danø K
Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand-binding domain.
The Journal of biological chemistry 1992;267(25):18224-9.
1992: Ploug M; Eriksen J; Plesner T; Hansen N E; Danø K
A soluble form of the glycolipid-anchored receptor for urokinase-type plasminogen activator is secreted from peripheral blood leukocytes from patients with paroxysmal nocturnal hemoglobinuria.
European journal of biochemistry / FEBS 1992;208(2):397-404.
1992: Olson D; Pöllänen J; Høyer-Hansen G; Rønne E; Sakaguchi K; Wun T C; Appella E; Danø K; Blasi F
Internalization of the urokinase-plasminogen activator inhibitor type-1 complex is mediated by the urokinase receptor.
The Journal of biological chemistry 1992;267(13):9129-33.
1992: Solberg H; Løber D; Eriksen J; Ploug M; Rønne E; Behrendt N; Danø K; Høyer-Hansen G
Identification and characterization of the murine cell surface receptor for the urokinase-type plasminogen activator.
European journal of biochemistry / FEBS 1992;205(2):451-8.
1992: Lund L R; Danø K
Okadaic acid strongly increases gene transcription, mRNA and protein level for the urokinase receptor in human A549 cells.
FEBS letters 1992;298(2-3):177-81.
1991: Kristensen P; Eriksen J; Blasi F; Danø K
Two alternatively spliced mouse urokinase receptor mRNAs with different histological localization in the gastrointestinal tract.
The Journal of cell biology 1991;115(6):1763-71.
1991: Rømer J; Lund L R; Eriksen J; Ralfkiaer E; Zeheb R; Gelehrter T D; Danø K; Kristensen P
Differential expression of urokinase-type plasminogen activator and its type-1 inhibitor during healing of mouse skin wounds.
The Journal of investigative dermatology 1991;97(5):803-11.
1991: Lund L R; Rømer J; Rønne E; Ellis V; Blasi F; Danø K
Urokinase-receptor biosynthesis, mRNA level and gene transcription are increased by transforming growth factor beta 1 in human A549 lung carcinoma cells.
The EMBO journal 1991;10(11):3399-407.
1991: Quax P H; van Muijen G N; Weening-Verhoeff E J; Lund L R; Danø K; Ruiter D J; Verheijen J H
Metastatic behavior of human melanoma cell lines in nude mice correlates with urokinase-type plasminogen activator, its type-1 inhibitor, and urokinase-mediated matrix degradation.
The Journal of cell biology 1991;115(1):191-9.
1991: Quax P H; Pedersen N; Masucci M T; Weening-Verhoeff E J; Danø K; Verheijen J H; Blasi F
Complementation between urokinase-producing and receptor-producing cells in extracellular matrix degradation.
Cell regulation 1991;2(10):793-803.
1991: Pyke C; Kristensen P; Ralfkiaer E; Eriksen J; Danø K
The plasminogen activation system in human colon cancer: messenger RNA for the inhibitor PAI-1 is located in endothelial cells in the tumor stroma.
Cancer research 1991;51(15):4067-71.
1991: Rønne E; Behrendt N; Ellis V; Ploug M; Danø K; Høyer-Hansen G
Cell-induced potentiation of the plasminogen activation system is abolished by a monoclonal antibody that recognizes the NH2-terminal domain of the urokinase receptor.
FEBS letters 1991;288(1-2):233-6.
1991: Ellis V; Behrendt N; Danø K
Plasminogen activation by receptor-bound urokinase. A kinetic study with both cell-associated and isolated receptor.
The Journal of biological chemistry 1991;266(19):12752-8.
1991: Ellis V; Danø K
Plasminogen activation by receptor-bound urokinase.
Seminars in thrombosis and hemostasis 1991;17(3):194-200.
1991: Ploug M; Behrendt N; Løber D; Danø K
Protein structure and membrane anchorage of the cellular receptor for urokinase-type plasminogen activator.
Seminars in thrombosis and hemostasis 1991;17(3):183-93.
1991: Pyke C; Kristensen P; Ralfkiaer E; Grøndahl-Hansen J; Eriksen J; Blasi F; Danø K
Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas.
The American journal of pathology 1991;138(5):1059-67.
1991: Behrendt N; Ploug M; Patthy L; Houen G; Blasi F; Danø K
The ligand-binding domain of the cell surface receptor for urokinase-type plasminogen activator.
The Journal of biological chemistry 1991;266(12):7842-7.
1991: Kristensen P; Eriksen J; Danø K
Localization of urokinase-type plasminogen activator messenger RNA in the normal mouse by in situ hybridization.
The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 1991;39(3):341-9.
1991: Lund L R; Rønne E; Roldan A L; Behrendt N; Rømer J; Blasi F; Danø K
Urokinase receptor mRNA level and gene transcription are strongly and rapidly increased by phorbol myristate acetate in human monocyte-like U937 cells.
The Journal of biological chemistry 1991;266(8):5177-81.
1991: Ploug M; Rønne E; Behrendt N; Jensen A L; Blasi F; Danø K
Cellular receptor for urokinase plasminogen activator. Carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol.
The Journal of biological chemistry 1991;266(3):1926-33.
1990: Ellis V; Wun T C; Behrendt N; Rønne E; Danø K
Inhibition of receptor-bound urokinase by plasminogen-activator inhibitors.
The Journal of biological chemistry 1990;265(17):9904-8.
1990: Behrendt N; Rønne E; Ploug M; Petri T; Løber D; Nielsen L S; Schleuning W D; Blasi F; Appella E; Danø K
The human receptor for urokinase plasminogen activator. NH2-terminal amino acid sequence and glycosylation variants.
The Journal of biological chemistry 1990;265(11):6453-60.
1990: Hansen S H; Behrendt N; Danø K; Kristensen P
Localization of urokinase-type plasminogen activator receptor on U937 cells: phorbol ester PMA induces heterogeneity.
Experimental cell research 1990;187(2):255-62.
1990: Roldan A L; Cubellis M V; Masucci M T; Behrendt N; Lund L R; Danø K; Appella E; Blasi F
Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis.
The EMBO journal 1990;9(2):467-74.
1990: Kristensen P; Pyke C; Lund L R; Andreasen P A; Danø K
Plasminogen activator inhibitor-type 1 in Lewis lung carcinoma.
Histochemistry 1990;93(6):559-66.
1989: Cubellis M V; Andreasen P; Ragno P; Mayer M; Danø K; Blasi F
Accessibility of receptor-bound urokinase to type-1 plasminogen activator inhibitor.
Proceedings of the National Academy of Sciences of the United States of America 1989;86(13):4828-32.
1989: Stephens R W; Pöllänen J; Tapiovaara H; Leung K C; Sim P S; Salonen E M; Rønne E; Behrendt N; Danø K; Vaheri A
Activation of pro-urokinase and plasminogen on human sarcoma cells: a proteolytic system with surface-bound reactants.
The Journal of cell biology 1989;108(5):1987-95.
1989: Salonen E M; Vaheri A; Pöllänen J; Stephens R; Andreasen P; Mayer M; Danø K; Gailit J; Ruoslahti E
Interaction of plasminogen activator inhibitor (PAI-1) with vitronectin.
The Journal of biological chemistry 1989;264(11):6339-43.
1989: Picone R; Kajtaniak E L; Nielsen L S; Behrendt N; Mastronicola M R; Cubellis M V; Stoppelli M P; Pedersen S; Danø K; Blasi F
Regulation of urokinase receptors in monocytelike U937 cells by phorbol ester phorbol myristate acetate.
The Journal of cell biology 1989;108(2):693-702.
1989: Georg B; Helseth E; Lund L R; Skandsen T; Riccio A; Danø K; Unsgaard G; Andreasen P A
Tumor necrosis factor-alpha regulates mRNA for urokinase-type plasminogen activator and type-1 plasminogen activator inhibitor in human neoplastic cell lines.
Molecular and cellular endocrinology 1989;61(1):87-96.
1989: Eriksen J; Kristensen P; Pyke C; Danø K
Plasminogen activator inhibitor (type-1) in rat adrenal medulla.
Histochemistry 1989;92(5):377-83.
1988: Lund L R; Georg B; Nielsen L S; Mayer M; Danø K; Andreasen P A
Plasminogen activator inhibitor type 1: cell-specific and differentiation-induced expression and regulation in human cell lines, as determined by enzyme-linked immunosorbent assay.
Molecular and cellular endocrinology 1988;60(1):43-53.
1988: Mayer M; Lund L R; Riccio A; Skouv J; Nielsen L S; Stacey S N; Danø K; Andreasen P A
Plasminogen activator inhibitor type-1 protein, mRNA and gene transcription are increased by phorbol esters in human rhabdomyosarcoma cells.
The Journal of biological chemistry 1988;263(30):15688-93.
1988: Petersen L C; Lund L R; Nielsen L S; Danø K; Skriver L
One-chain urokinase-type plasminogen activator from human sarcoma cells is a proenzyme with little or no intrinsic activity.
The Journal of biological chemistry 1988;263(23):11189-95.
1988: Grøndahl-Hansen J; Lund L R; Ralfkiaer E; Ottevanger V; Danø K
Urokinase- and tissue-type plasminogen activators in keratinocytes during wound reepithelialization in vivo.
The Journal of investigative dermatology 1988;90(6):790-5.
1988: Riccio A; Lund L R; Sartorio R; Lania A; Andreasen P A; Danø K; Blasi F
The regulatory region of the human plasminogen activator inhibitor type-1 (PAI-1) gene.
Nucleic acids research 1988;16(7):2805-24.
1988: Nielsen L S; Kellerman G M; Behrendt N; Picone R; Danø K; Blasi F
A 55,000-60,000 Mr receptor protein for urokinase-type plasminogen activator. Identification in human tumor cell lines and partial purification.
The Journal of biological chemistry 1988;263(5):2358-63.
1988: Pöllänen J; Hedman K; Nielsen L S; Danø K; Vaheri A
Ultrastructural localization of plasma membrane-associated urokinase-type plasminogen activator at focal contacts.
The Journal of cell biology 1988;106(1):87-95.
1988: Grøndahl-Hansen J; Agerlin N; Munkholm-Larsen P; Bach F; Nielsen L S; Dombernowsky P; Danø K
Sensitive and specific enzyme-linked immunosorbent assay for urokinase-type plasminogen activator and its application to plasma from patients with breast cancer.
The Journal of laboratory and clinical medicine 1988;111(1):42-51.
1987: Andreasen P A; Pyke C; Riccio A; Kristensen P; Nielsen L S; Lund L R; Blasi F; Danø K
Plasminogen activator inhibitor type 1 biosynthesis and mRNA level are increased by dexamethasone in human fibrosarcoma cells.
Molecular and cellular biology 1987;7(8):3021-5.
1987: Pöllänen J; Saksela O; Salonen E M; Andreasen P; Nielsen L; Danø K; Vaheri A
Distinct localizations of urokinase-type plasminogen activator and its type 1 inhibitor under cultured human fibroblasts and sarcoma cells.
The Journal of cell biology 1987;104(4):1085-96.
1986: Andreasen P A; Riccio A; Welinder K G; Douglas R; Sartorio R; Nielsen L S; Oppenheimer C; Blasi F; Danø K
Plasminogen activator inhibitor type-1: reactive center and amino-terminal heterogeneity determined by protein and cDNA sequencing.
FEBS letters 1986;209(2):213-8.
1986: Andreasen P A; Nielsen L S; Kristensen P; Grøndahl-Hansen J; Skriver L; Danø K
Plasminogen activator inhibitor from human fibrosarcoma cells binds urokinase-type plasminogen activator, but not its proenzyme.
The Journal of biological chemistry 1986;261(17):7644-51.
1986: Andreasen P A; Christensen T H; Huang J Y; Nielsen L S; Wilson E L; Danø K
Hormonal regulation of extracellular plasminogen activators and Mr approximately 54,000 plasminogen activator inhibitor in human neoplastic cell lines, studied with monoclonal antibodies.
Molecular and cellular endocrinology 1986;45(2-3):137-47.
1986: Nielsen L S; Andreasen P A; Grøndahl-Hansen J; Huang J Y; Kristensen P; Danø K
Monoclonal antibodies to human 54,000 molecular weight plasminogen activator inhibitor from fibrosarcoma cells--inhibitor neutralization and one-step affinity purification.
Thrombosis and haemostasis 1986;55(2):206-12.
1986: Nielsen L S; Andreasen P A; Grøndahl-Hansen J; Skriver L; Danø K
Plasminogen activators catalyse conversion of inhibitor from fibrosarcoma cells to an inactive form with a lower apparent molecular mass.
FEBS letters 1986;196(2):269-73.
1986: Nielsen L S; Grøndahl-Hansen J; Andreasen P A; Skriver L; Zeuthen J; Danø K
Enzyme-linked immunosorbent assay for human urokinase-type plasminogen activator and its proenzyme using a combination of monoclonal and polyclonal antibodies.
Journal of immunoassay 1986;7(3):209-28.
1985: Grøndahl-Hansen J; Nielsen L S; Kristensen P; Grøndahl-Hansen V; Andreasen P A; Danø K
Plasminogen activator in psoriatic scales is of the tissue-type PA as identified by monoclonal antibodies.
The British journal of dermatology 1985;113(3):257-63.
1985: Kielberg V; Andreasen P A; Grøndahl-Hansen J; Nielsen L S; Skriver L; Danø K
Proenzyme to urokinase-type plasminogen activator in the mouse in vivo.
FEBS letters 1985;182(2):441-5.
1985: Danø K; Andreasen P A; Grøndahl-Hansen J; Kristensen P; Nielsen L S; Skriver L
Plasminogen activators, tissue degradation, and cancer.
Advances in cancer research 1985;44():139-266.
1984: Skriver L; Larsson L I; Kielberg V; Nielsen L S; Andresen P B; Kristensen P; Danø K
Immunocytochemical localization of urokinase-type plasminogen activator in Lewis lung carcinoma.
The Journal of cell biology 1984;99(2):753-7.
1984: Kristensen P; Larsson L I; Nielsen L S; Grøndahl-Hansen J; Andreasen P A; Danø K
Human endothelial cells contain one type of plasminogen activator.
FEBS letters 1984;168(1):33-7.
1984: Larsson L I; Skriver L; Nielsen L S; Grøndahl-Hansen J; Kristensen P; Danø K
Distribution of urokinase-type plasminogen activator immunoreactivity in the mouse.
The Journal of cell biology 1984;98(3):894-903.
1984: Andreasen P A; Nielsen L S; Grøndahl-Hansen J; Skriver L; Zeuthen J; Stephens R W; Danø K
Inactive proenzyme to tissue-type plasminogen activator from human melanoma cells, identified after affinity purification with a monoclonal antibody.
The EMBO journal 1984;3(1):51-6.
1983: Nielsen L S; Hansen J G; Andreasen P A; Skriver L; Danø K; Zeuthen J
Monoclonal antibody to human 66,000 molecular weight plasminogen activator from melanoma cells. Specific enzyme inhibition and one-step affinity purification.
The EMBO journal 1983;2(1):115-9.
1983: Skriver L; Nielsen L S; Kristensen P; Danø K
[Biochemical mechanism for extracellular proteolysis. Tissue destruction and cancer]
Nordisk medicin 1983;98(10):238-41.
1982: Nielsen L S; Hansen J G; Skriver L; Wilson E L; Kaltoft K; Zeuthen J; Danø K
Purification of zymogen to plasminogen activator from human glioblastoma cells by affinity chromatography with monoclonal antibody.
Biochemistry 1982;21(25):6410-5.
1982: Danø K; Dabelsteen E; Nielsen L S; Kaltoft K; Wilson E L; Zeuthen J
Plasminogen activating enzyme in cultured glioblastoma cells. An immunofluorescence study with monoclonal antibody.
The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 1982;30(11):1165-70.
1982: Kaltoft K; Nielsen L S; Zeuthen J; Danø K
Monoclonal antibody that specifically inhibits a human Mr 52,000 plasminogen-activating enzyme.
Proceedings of the National Academy of Sciences of the United States of America 1982;79(12):3720-3.
1982: Skriver L; Nielsen L S; Stephens R; Danø K
Plasminogen activator released as inactive proenzyme from murine cells transformed by sarcoma virus.
European journal of biochemistry / FEBS 1982;124(2):409-14.

Sign-in to see more